The majority of the population is infected by several herpesviruses. Once these infections are established the viruses persist for life. Therefore, current therapy may at best reduce symptoms but does not cure the infection. Moreover, the only classes of compounds licensed for systemic treatment of disease are nucleoside, nucleotide and pyrophosphate analogues; all of these ultimately target the herpesvirus DNA polymerase. A vaccine against varicella zoster virus (VZV) is available, but so far no effective vaccines against other human herpesviruses have been launched. At the same time, rising resistance to current medication, especially in the immunocompromised patient population, is a concern. For these reasons, there is an urgent need for new treatment options. Recently, some promising new drugs have been discovered; one of these compounds, developed at Bayer HealthCare under the name BAY 57-1293, is a potent HSV helicase primase inhibitor.
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Herpesviruses are thought to have co-evolved with animals (Knipe & Howley, 2001) and have plagued humanity since ancient times . Nine human herpesviruses have been identified and linked to disease, to date ( Table 1 ). The majority of these infections are generally self-limiting in immunocompetent patients, but common conditions caused by HSV (such as recurrent cold sores and genital or ocular herpes) interfere with everyday activities and can result in psychosocial distress to the patient, especially affecting personal relationships. In neonates and immunocompromised patients, such as transplant recipients and cancer and AIDS patients, HSV disease can be more severe or even life-threatening (www.ihmf.org).
The virus is transmitted by close contact usually via mucocutaneous junctions (Knipe & Howley, 2001; Kleymann, 2003) . The immune responses clear the infectious virus from local tissues, but immune escape or evasion mechanisms of the virus allow latency to be established (Knipe & Howley, 2001; Koelle & Corey, 2003) . The α herpesviruses (HSV, VZV) infect nerve endings of sensory neurons and establish lifelong latency in ganglionic neurons innervating the site of primary infection. From this reservoir of latently infected cells, the virus reactivates upon diverse stimuli, such as fever, illness, immune suppression and UV light, causing chronically persistent recurrent disease.
Historical aspects and current therapy
Epoch-making discoveries in virology have been accomplished in the herpesvirus field (Field & De Clercq, 2004) . Idoxuridine (IDU) was the first antiviral nucleoside for topical treatment of HSV keratitis (Prusoff, 1959; Kaufman, 1962) , and was soon joined by trifluridine (TFT; Kaufman, 1964) and the first systemic anti-herpes nucleoside adenine arabinoside (Ara-A, vidarabine) for treatment of the potentially fatal disease herpes encephalitis (Whitley et al., 1977) . These studies were published in the early 1960s and late 1970s, respectively. Acyclovir (Zovirax TM ), the first highly selective and specific inhibitor of viral DNA replication, was a true milestone in the development of antiviral drugs in the late 1970s (Elion et al., 1977; Vectavir TM ) and the orally bioavailable pro-drugs valacyclovir (VACV, Valtrex TM ) and famciclovir (FCV, Famvir TM ), were launched in the mid-1990s as ACV became a generic drug (Knipe & Howley, 2001; Kleymann, 2003) . The current therapeutic options (Table 1) , second line therapy for drug-resistant viral strains and a contemporary interpretation of the challenge to establish novel treatments for herpes disease have all been reviewed (Coen & Schaffer, 2003; Eizuru, 2003; Kleymann, 2003) .
The search for new anti-herpes drugs
Current therapy (www.ihmf.org, www.pdr.net), however, does not eradicate latent virus and symptoms can be significantly reduced only if treatment is prophylactic (for example, long-term suppressive therapy) or initiated early during primary or recurrent disease. Therefore, efficacy upon delayed treatment, safety and activity against strains with acquired resistance to nucleosides were key criteria during the search for the next generation of drugs, directed at novel antiviral targets (Coen & Schaffer, 2003; Eizuru, 2003; Kleymann, 2003) .
The genome sequences of all nine human herpesviruses have been published and the accession numbers are shown (Table 1 ). More than 50 of the 80-plus genes in the herpesviruses are essential for viral replication in vitro and/or in vivo and, in principle, all are potential targets for effective antiviral agents.
As mentioned above, all major drugs that have been marketed for systemic therapy of herpes disease to date are nucleoside, nucleotide or pyrophosphate mimetics that ultimately target herpesvirus DNA polymerase. Some recent drug candidates have extended the range of targets to include helicase primase, DNA encapsidation, viral protein kinase or even cellular proteins (Knipe & Howley, 2001; Coen & Schaffer, 2003; Eizuru, 2003; Kleymann, 2003) .
Discovery of helicase primase inhibitors
The discovery of helicase primase inhibitors represented a challenge to the supremacy of DNA polymerase as the ultimate target for herpesvirus inhibitors. In recent years, there has been another important breakthrough in the development of antiviral agents against HSV with the discovery of molecules that interact with viral helicase primase (Crute et al., 2002; Kleymann et al. 2002; Crumpacker & Schaffer, 2002) . The first helicase primase inhibitors were described by several companies (Kleymann, 2003a) . Merck did not report on the (now obvious) mechanism of action for their compound ER622 which is active in cell culture experiments. Tularik identified compound T175602 with a biochemical-helicase assay as a screen (Spector et al., 1998) , but no in-vivo data were reported. Parallel to these studies, Crute at Boehringer/Biomega (Crute et al., 2002) using a similar approach and Kleymann at Bayer Kleymann & Werling, 2004a; Kleymann & Werling, 2004b) following a different strategy independently discovered the same generic screening hits (Kleymann, 2003a) . While researchers at Merck apparently focused on the herpes protease, and Tularik discontinued research activities with respect to the aminothiazolylphenylcontaining class of compounds and presented a nitropyrimidine HCMV helicase inhibitor T-0902611 at ICAAC 2001 (Coen & Schaffer, 2003) , the researchers at Boehringer optimized the screening hits to promising aminothiazolylphenyl-containing lead compounds (Crute et al., 2002; Duan et al., 2003) . Unfortunately this project was also terminated due to a shift in business focus before the leads could be optimized to final development drug candidates. In addition to the drug classes described above, the novel thiazole urea class of compounds was discovered . This project at Bayer was pursued until no further improvements with respect to activity in animal models of human disease were achieved. Finally, BAY 57-1293, a thiazolyl amide-containing compound with a drug-like profile, was selected for clinical development from a panel of several drug candidates. It appears that BAY 57-1293 and close analogues are the most efficacious compounds to treat HSV disease to date, as judged in a series of relevant animal infection models Betz et al., 2002 , Kleymann, 2003b . Surprisingly, the pharmacophores of the thiazole urea and aminothiazolylphenyl-containing compounds can be fused to an antiviral compound (Kleymann, 2003a) , linking the SAR of more than 1000 compounds to a unifying pharmacophore model (Kleymann, 2003a; Kleymann, 2004) .
Drug candidate BAY 57-1293
The superior efficacy of helicase primase inhibitors is based on an antiviral activity that is two orders of magnitude more potent in cell culture than the gold standard acyclovir and, combined with a favourable pharmacokinetic profile, this makes BAY 57-1293 the most potent drug candidate in vivo (Kleymann, 2003b) . Due to the different mechanism of action ( Figure 1 ) BAY 57-1293 is active against clinical isolates resistant to current chemotherapeutic compounds Kleymann et al., submitted) .
The physiochemical properties of BAY 57-1293 allow for development of topical, oral and intravenous formulations to suppress or treat primary and recurrent HSV diseases such as herpes labialis, herpes genitalis, keratoconjunctivitis, gingivostomatitis, pharyngitis, mucocutaneous herpes, herpes encephalitis, meningoencephalitis, ©2004 International Medical Press Simplified cartoon of HSV DNA synthesis (Boehmer & Nimonkar, 2003) . The helicase-primase complex, consisting of proteins encoded by viral genes U L 5 (helicase), U L 8 and U L 52 (primase), unwinds HSV DNA at the replication fork and primes both lagging-strand and leading-strand DNA synthesis. ICP-8 (grey) binds to single-stranded template DNA. HSV DNA polymerase (U L 30) and its accessory protein (U L 42) perform leadingand lagging-strand DNA synthesis. The arrows indicate the direction of movement of the DNA replication proteins. The new drugs target the helicase-primase complex (Kleymann, 2003a) . Amino-thiazolyl-phenyl-containing compounds, thiazole urea and thiazole amide derivatives enhance binding of the U L 5 and U L 52 subunits of the helicase-primase complex to both leading and lagging-strand DNA resulting in inhibition of helicase activity, primase activity and viral DNA synthesis. Acyclovir (triphosphate) binds to HSV DNA polymerase, inhibiting polymerase activity and synthesis of both leading and lagging DNA strands. The ssDNA binding core and the ADP binding site of Rep, a homologous helicase (Korolev et al., 1997; IUAA.PDB) are depicted in the center. Residues involved in binding ssDNA are indicated in yellow. Residues involved in binding ADP are indicated in gold. ssDNA is in purple and ADP is indicated in green. Motif II is indicated in dark blue. The arrow points at the homologous U L 5 helix where resistance conferring mutations were localized Kleymann et al., submitted) . neonatal herpes and disseminated or visceral HSV infections (oesophagitis, pneumonia or hepatitis).
Clinical trials will have to demonstrate whether the excellent in vitro activity, the superior efficacy in animal models and the favourable pharmacokinetic and safety profiles will open the way to a novel non-nucleoside treatment of herpes simplex disease.
Relevant parameters of a potential product profile of BAY 57-1293 are compared in Table 4 of reference Kleymann, 2003b . The potency and efficacy of BAY 57-1293 compared with VACV, even using a once daily regimen and especially when treatment is delayed, are encouraging for clinical trials and may result in reduced mortality and morbidity of severe herpes disease (such as herpes encephalitis or disseminated disease), significant shortening of time to healing compared with established therapy and a decreased likelihood of direct rebound of disease after cessation of treatment. Almost complete inhibition of viral shedding results in effective suppression therapy, raising the hope of reducing viral spread. The effective inhibition of viral propagation in vivo correlates with a superior IC 50 as a function of increasing viral load, i.e. multiplicity of infection in vitro, a situation observed for the smallest unit of infection and during development of disease symptoms in vivo.
The remarkable effect of reduced recurrences after therapy of primary HSV disease with BAY 57-1293 in animal models remains to be confirmed in the clinic. The preliminary data are intriguing and suggest for the first time that a compound may have an effect on establishment and/or reactivation from latency. Overall this class of drugs has significant potential for treating HSV disease, including strains resistant to current therapeutics.
Conclusion
Current therapy is relatively safe and has moderate activity to reduce symptoms of disease. Considering growing drug resistance, especially in the immunocompromised patient population, and the absence of vaccines against the majority of herpesviruses, having only one treatment option (nucleosidic drugs) for herpes simplex disease is clearly not in the public interest. Recently, many pharmaceutical companies have discontinued their activities in the herpes indication assuming that technical feasibility is difficult and a viable business model is hard to achieve, though less than one in ten patients is treated. Thus, the risk/return ratio and the market entry barrier are high. BAY 57-1293 will have to undertake the hurdle of clinical trials and subsequent market entry for herpes simplex indication (Kleymann, 2003; Coen & Schaffer, 2003) . A successful launch of treatment options that are superior to existing medications would represent a major advance in therapy.
A last word with respect to the nomenclature of the compound class: first screening hits, such as BAY 38-9489 , are thiazole urea compounds; however, BAY 57-1293 is a thiazole amide, and not a thiazole urea compound, as incorrectly stated in numerous review articles (Coen & Schaffer, 2003; Eizuru, 2003; Crumpacker & Schaffer, 2002; Frick, 2003) .
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